UK: A Green Light For Business? The Rescheduling Of Cannabis-Derived Medicinal Products And The UK's Anti-Money Laundering Regime

Last Updated: 7 December 2018
Article by David Hardstaff and Daniel Jackson

In July 2018, Home Secretary, Sajid Javid, announced that certain cannabis-derived medicinal products would be rescheduled under the Misuse of Drugs Regulations 2001 ('the MDA Regulations'). This followed the widely reported cases of Billy Caldwell and Alfie Dingley who were granted Home Office controlled drug licences, enabling them to access cannabis oil to reduce epileptic seizures. The Government's plans are progressing with this week seeing the NHS issue guidance to clinicians in anticipation of the rescheduling taking place, and the laying of regulations in Parliament, which subject to annulment by either of the Houses of Parliament, will come into force on 1 November 2018.

While the stories of Billy and Alfie may have been the catalyst behind the Government's move, the picture internationally is of an industry that is growing at an exponential rate, with experts estimating that the global market in cannabis-derived products could be worth over $140 billion by the end of 2025. The market in medicinal products in particular is set to be truly international, with major players in the pharmaceutical and financial industries making moves to consolidate their positions in anticipation of what has been dubbed the 'green rush'. Against this backdrop, these developments will undoubtedly be good news for UK investors, keen to support this exciting and progressive industry both at home and abroad. However, despite recent developments, the UK's anti-money laundering regime looms large.

Controlled drugs and the law

A casual observer could be forgiven for thinking that the UK is heading in the same direction as Canada, where from 17 October 2018 it has been legal to produce, distribute, sell and possess cannabis, subject to complying with the provisions of the Canadian Cannabis Act. This is far from the case. Under the UK's Misuse of Drugs Act 1971 ('the MDA') cannabis is, and will remain, a Class B controlled drug, which means it is an offence to cultivate, supply or possess cannabis without a controlled drug licence issued by the Home Office or the Medicines and Healthcare products Regulatory Agency. However, with the announcement that certain cannabis-derived medicinal products will be moved from Schedule 1 of the MDA Regulations to Schedule 2 – which lists drugs that have therapeutic value, but are highly addictive – it should become significantly easier for healthcare professionals to prescribe a wide-range of new or previously inaccessible products. There is already precedent for this; in 2010, GW Pharmaceuticals was granted a licence for the sale of their cannabis-derived medicine, Sativex, which is listed in Schedule 4 of the MDA Regulations.

Proceeds of crime

Where a controlled drug licence has been issued, any property generated as a result of associated commercial activities will not constitute criminal property within the meaning of the Proceeds of Crime Act 2002 ('POCA'), the UK's principal anti-money laundering legislation. The regime therefore provides a level of certainty for those who wish to do business and invest in the UK's own domestic cannabis industry. The position is not as straightforward when dealing with property generated through overseas cannabis industries.

Sections 327-329 of POCA prohibit virtually any action in respect of criminal property, from concealing, converting and transferring to merely acquiring or possessing. Each section also includes a defence where a person knows or believes that the relevant criminal conduct occurred in a particular country outside of the UK, and the relevant criminal conduct was not unlawful under the criminal law in that country. This is known as the overseas conduct defence. However, with a few exceptions, the Proceeds of Crime Act 2002 (Money Laundering: Exceptions to Overseas Conduct Defence) Order 2006 ('the 2006 Order') effectively removes the overseas conduct defence for all conduct that would constitute an offence punishable by imprisonment for a maximum term in excess of 12 months if it occurred in the UK. The rationale behind the UK's policy is that it is a money laundering offence to deal with 'property' which represents the proceeds of activity which would be a crime in the UK, even if that activity is lawful in the country in which it is carried out. 'Property' in this sense, includes income or revenue and any property traceable to that income or revenue.

The implications of the 2006 Order for UK investors hoping to do business in relation to overseas cannabis industries – such as in Canada, Uruguay and Jamaica – are far from straightforward. Taking the imminent change in the law in Canada as an example, as possession of cannabis for recreational use would be criminal conduct in the UK (punishable by up to 5 years' imprisonment), any benefit derived from the same conduct in Canada would constitute criminal property if that property were to find its way onto the UK's shores. Therefore, an individual or corporate entity in the UK undertaking any of the activities set out at sections 327–329 of POCA in relation to any such criminal property would be at risk of committing a money laundering offence.

In cases where lawful conduct overseas could also be lawful in the UK because it could be carried out under the UK's licensing regime, careful consideration must be given to whether the respective licensing regimes correspond closely enough to avoid criminal liability. A 'like for like' comparison of the UK's controlled drug licensing regime with that of another country is unlikely to be straightforward, with issues unique to the respective jurisdictions complicating the process. Equally, the question of how closely the two regimes would have to correspond to avoid criminal liability is far from clear. The recent announcement by the major insurance market, Lloyd's, that it was satisfied that providing insurance for cannabis-related business in Canada would not breach POCA suggests that this is an issue experts are already considering in some detail.

Amber to green light

In the event of uncertainty as to whether property emanating from overseas represents criminal property, a suspicious activity report, or 'SAR', can be submitted to the National Crime Agency with a request for consent to proceed with a particular transaction (such consent amounting to a defence to the section 327-329 offences). However, the process of obtaining consent can be a lengthy and risks stifling business. On the other hand, the consequences of committing an offence under POCA are serious, with money laundering offences carrying sentences of imprisonment and the risk of freezing orders and confiscation proceedings. In view of these risks, it is inevitable that the impact of the Home Secretary's announcement will be slower to take effect in relation to international trade and investment than in relation to trade and investment within the UK's own domestic licensed cannabis industry. Despite this, and whatever the pace of change, it is clear that this humble plant is going to be big business.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions